Key result
Peri-procedural RBC transfusion linked to higher mortality and complications after TAVR.
Why the study?
Does peri-procedural red blood cell transfusion increase the risk of mortality and cardiovascular complications in adults undergoing TAVR?
Cohort (n=82,840)
Yes
Does peri-procedural red blood cell transfusion increase the risk of mortality and cardiovascular complications in adults undergoing TAVR?
Relative Risk: 3.933 (95% CI 2.27–6.92)
p-value: p=< 0.001
Peri-procedural red blood cell transfusion during TAVR is associated with significantly increased short-term mortality and complications, supporting the use of restrictive transfusion strategies.
Supports restrictive transfusion strategies in TAVR; reinforces observational data on transfusion-associated harm.
BACKGROUND: Red blood cell (RBC) transfusion is common after transcatheter aortic valve replacement (TAVR) to manage peri-procedural bleeding and has been associated with adverse outcomes in various studies. However, the prognostic impact of peri-procedural transfusion in TAVR patients remains unclear. This study aimed to assess the impact of peri-procedural RBC transfusion on cardiovascular outcomes in TAVR patients compared to those without transfusion. METHODS: A retrospective cohort study was conducted using the TriNetX US Collaborative Research Network, including adults undergoing TAVR until August 31, 2025. Patients were divided into those receiving RBC transfusion (n = 3,176) and those without (n = 79,664) on the day of receiving TAVR. Propensity score matching (1:1) balanced cohorts (n = 3161 each) for demographics, comorbidities, medications, and laboratory values. Relative risks (RR) and hazard ratios (HR) were calculated using propensity-matched and Cox proportional hazard models. RESULTS: Transfused patients had significantly higher all-cause mortality (RR 3.933; 95% CI: 2.27-6.92; p < 0.001 at 7 days; RR 1.824; 95% CI: 1.466-2.268; p < 0.001 at 3 months). Secondary outcomes showed elevated risks for MACE (RR 1.324; 95% CI: 1.073-1.633; p = 0.009 at 7 days; RR 1.199; 95% CI: 1.060-1.358; p = 0.004 at 3 months), hemodynamic instability (RR 2.063; 95% CI: 1.655-2.571; p < 0.001 at 7 days; RR 1.638; 95% CI: 1.368-1.962; p < 0.001 at 3 months), acute kidney injury (RR 1.615; 95% CI: 1.295-2.013; p < 0.001 at 7 days; RR 1.379; 95% CI: 1.196-1.591; p < 0.001 at 3 months), and post-TAVR sepsis (RR 1.184; 95% CI: 0.771-1.819; p = 0.439 at 30 days; RR 0.899; 95% CI: 0.667-1.211; p = 0.483 at 3 months). Ischemic stroke/TIA risk was modestly increased in unadjusted analyses but attenuated post-matching (RR 1.123; 95% CI: 0.823-1.534; p = 0.464 at 7 days; RR 1.219; 95% CI: 0.995-1.493; p = 0.056 at 3 months). Cox models showed statistically significant risk elevations for most outcomes, including heart failure exacerbation (HR 1.418; 95% CI: 1.311-1.533; p < 0.001). CONCLUSIONS: Peri-procedural RBC transfusion was associated with increased risks of mortality and complications after TAVR, with attenuation over time. These findings support consideration of restrictive transfusion strategies.
No takes yet. Share an insight, caveat, or question.
Qadeer et al. (2026) conducted a cohort in Transcatheter aortic valve replacement (TAVR) (n=82,840). Peri-procedural red blood cell (RBC) transfusion vs. No RBC transfusion was evaluated on All-cause mortality at 7 days (RR 3.933, 95% CI 2.27-6.92, p=< 0.001). Peri-procedural RBC transfusion during TAVR was associated with significantly higher all-cause mortality at 7 days (RR 3.933; 95% CI 2.27-6.92; p<0.001) compared to no transfusion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: